首页> 外文OA文献 >Odin (ANKS1A) is a Src family kinase target in colorectal cancer cells.
【2h】

Odin (ANKS1A) is a Src family kinase target in colorectal cancer cells.

机译:Odin(ANKS1A)是结直肠癌细胞中的Src家族激酶靶标。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BACKGROUND: Src family kinases (SFK) are implicated in the development of some colorectal cancers (CRC). One SFK member, Lck, is not detectable in normal colonic epithelium, but becomes aberrantly expressed in a subset of CRCs. Although SFK have been extensively studied in fibroblasts and different types of immune cells, their physical and functional targets in many epithelial cancers remain poorly characterised. RESULTS: 64 CRC cell lines were tested for expression of Lck. SW620 CRC cells, which express high levels of Lck and also contain high basal levels of tyrosine phosphorylated (pY) proteins, were then analysed to identify novel SFK targets. Since SH2 domains of SFK are known to often bind substrates after phosphorylation by the kinase domain, the LckSH2 was compared with 14 other SH2s for suitability as affinity chromatography reagent. Mass spectrometric analyses of LckSH2-purified pY proteins subsequently identified several proteins readily known as SFK kinase substrates, including cortactin, Tom1L1 (SRCASM), GIT1, vimentin and AFAP1L2 (XB130). Additional proteins previously reported as substrates of other tyrosine kinase were also detected, including the EGF and PDGF receptor target Odin. Odin was further analysed and found to contain substantially less pY upon inhibition of SFK activity in SW620 cells, indicating that it is a formerly unknown SFK target in CRC cells. CONCLUSION: Rapid identification of known and novel SFK targets in CRC cells is feasible with SH2 domain affinity chromatography. The elucidation of new SFK targets like Odin in epithelial cancer cells is expected to lead to novel insight into cancer cell signalling mechanisms and may also serve to indicate new biomarkers for monitoring tumor cell responses to drug treatments.
机译:背景:Src家族激酶(SFK)与某些大肠癌(CRC)的发生有关。在正常结肠上皮细胞中未检测到一个SFK成员Lck,但在一部分CRC中异常表达。尽管已经在成纤维细胞和不同类型的免疫细胞中对SFK进行了广泛的研究,但在许多上皮癌中其物理和功能靶标的表征仍然很差。结果:测试了64个CRC细胞系的Lck表达。然后分析SW620 CRC细胞,该细胞表达高水平的Lck,并且还包含高基础水平的酪氨酸磷酸化(pY)蛋白,以鉴定新的SFK靶标。由于已知SFK的SH2结构域经常被激酶结构域磷酸化后结合底物,因此将LckSH2与14种其他SH2进行了比较,以作为亲和色谱试剂。随后对LckSH2纯化的pY蛋白进行质谱分析,确定了几种容易被称为SFK激酶底物的蛋白,包括cortactin,Tom1L1(SRCASM),GIT1,波形蛋白和AFAP1L2(XB130)。还检测了先前报道为其他酪氨酸激酶底物的其他蛋白质,包括EGF和PDGF受体靶标Odin。对Odin进行了进一步分析,发现在SW620细胞中抑制SFK活性后,其pY含量要低得多,这表明它是CRC细胞中以前未知的SFK靶标。结论:SH2结构域亲和色谱法可以快速鉴定CRC细胞中已知和新型SFK靶标。上皮癌细胞中新的SFK靶标(如Odin)的阐明有望导致对癌细胞信号传导机制的新见解,也可能有助于指示新的生物标记物,以监测肿瘤细胞对药物治疗的反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号